author-photo

John Newcomb

Takeda Pharmaceutical Company

7

Papers

291

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (4)
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

2018 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (137)
Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor

2017 Nature Chemical Biology
Show All
- Source
- Cite
- Save
Citations (92)
Abstract 1147: Probing the roles of SUMOylation in cancer cell biology using a selective SUMO activating enzyme inhibitor

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.

2015 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (46)